β_2-微球蛋白在原发性肝癌鉴别诊断中的临床价值的探讨

Clinical evaluation of Serum β_2-microglobulin in differential diagnosis of hepatocarcinoma

目的探讨血清β2-MG在原发性肝癌鉴别诊断中的价值。方法采用放射免疫法测定正常人、肝癌、肝硬化、肝血管瘤患者血清中β2-MG,AFP的含量。结果肝癌患者β2-MG含量高于正常人、肝硬化、肝血管瘤患者。肝血管瘤患者与正常人血清β2-MG含量无明显差别。肝硬化患者血清β2-MG含量高于正常人,炎症型肝癌患者血清β2-MG含量高于单纯型、硬化型患者,血清β2-MG与AFP无相关关系。结论血清β2-MG是与AFP无关的、独立的肿瘤标记物之一,有助于肝癌、肝硬化、肝血管瘤的鉴别诊断。

[Objective] To study the clinical evaluation of serum β2-MG in diff erential diagnosis of hepatocarcinoma. [Methods] RIA method was used to measu re the levels of serum β2-MG and AFP of the health adults, patients with hepato carcinoma, liver cirrhosis (LC) and hepatic hemangioma. [Results] Serum β2-MG Levels of hepatocarcinoma were higher than that of the health adults , patients with LC and patients with hepatic hemangioma. In health adults and patients wit h hepatic hemangioma there was no significantly difference of β2-MG. Serum β2- MG Levels of patients with LC were higher than that of the health adults. And le vels of inflammatory type cases were significantly higher than that of simple ty pe and cirrhotic type cases in hepatocarcinoma. There was no relationship betwee n Serum β2-MG and AFP. [Conclusion] Serum β2-MG is a singly tumor marker an d has no relationship with AFP. The examination of serum β2-MG is helpful to th e differential diagnosis in hepatocarcinoma, LC and hepatic hemangioma.